Company: AZN
Filing Date: 2025-06-26
Form Type: 11-K
Source: 0001683168-25-004771
Chunk: 13

Company: ASTRAZENECA PLC
Filing Date: 2025-06-26
Form: 11-K
Chunk 13
---
 tax counsel believe that the Plan is designed and restated, and is currently being operated, in compliance with
the applicable requirements of the IRC and, therefore, believe that the Plan is qualified, and the related trust is tax-exempt.

Accounting
principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the plan and
recognize a tax liability (or asset) if the plan has taken an uncertain tax position that more likely than not would not be sustained
upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December
31, 2024, there are no uncertain tax positions taken or expected to be taken that would require recognition of a liability (or asset)
or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently
no audits for any tax periods in progress. The Plan administrator believes it is no longer subject to income tax examinations for years
prior to 2021.

| 6. | Plan Termination: |

Although
it has not expressed any intent to do so, the AstraZeneca North America HR Sub-Committee has the right under the Plan to amend or terminate
the Plan at any time, subject to the provisions of ERISA and other applicable laws. In the event of Plan termination, participants would
be 100 percent vested in their employer contributions.

| 7. | Party-in-Interest 
 Transactions:     |

Certain
Plan investments are shares of mutual funds managed by affiliates of Fidelity Investment Management Company. Fidelity Investment Management
Company is the trustee as defined in the Plan, and therefore, these transactions qualify as party-in-interest transactions.

The Plan also
invests in shares of AZ Common Stock, which qualifies as a party-in-interest transaction. As of December 3 I, 2024 and December 31, 2023,
the fair value of investments in AZ Common Stock was $139,748,329 and $158,431,850, respectively. During the year ended December 31,
2024, the Plan had purchases of $0 and had sales of $19,259,349 of AZ Common Stock. The total dividend income received during 2024 was
$3,408,610. The total realized and unrealized gain/(loss) during 2024 was $2,556,621.

| 8. | Risks and Uncertainties: |

The